# Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

> **NCT06367517** · — · RECRUITING · sponsor: **Medical University of Warsaw** · enrollment: 30 (estimated)

## Conditions studied

- Orbitopathy, Graves
- Thyroid Eye Disease
- Ophthalmopathy

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT06367517
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2025-05-20
- **Final completion:** 2026-05-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06367517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06367517, "Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06367517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*